Prostate cancer detection and dutasteride: Utility and limitations of prostate-specific antigen in men with previous negative biopsies

European Urology

Volumn 59, Issue 2, 2011, Pages 183-190

  Van Leeuwen, Pim J ^a   Kölble, Konrad ^b   Huland, Hartwig ^b   Hambrock, Thomas ^c   Barentsz, Jelle ^c   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 alpha reductase inhibitor; Biopsy; Chemoprevention; Dutasteride; Prostate cancer; PSA

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN;

AGED; CANCER DIAGNOSIS; CANCER STAGING; CASE REPORT; CLINICAL TRIAL (TOPIC); DIFFUSION WEIGHTED IMAGING; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; LYMPHADENECTOMY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; BIOPSY; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 78650716301     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.09.035     Document Type: Review

References (11)

1. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
2. I.M. Thompson, C. Chi, and D.P. Ankerst Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128 1133
3. I.M. Thompson, C.M. Tangen, and P.J. Goodman Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection J Urol 177 2007 1749 1752
4. L.S. Marks, G.L. Andriole, J.M. Fitzpatrick, C.C. Schulman, and C.G. Roehrborn The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations J Urol 176 2006 868 874
5. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
6. Andriole G, Bostwick, D, Brawley OW, et al. The effect of dutasteride on the utility of PSA for the diagnosis of high-grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. In press.
7. G. Andriole, D. Bostwick, and O. Brawley Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial J Urol 172 2004 1314 1317
8. P.C. Walsh Chemoprevention of prostate cancer N Engl J Med 362 2010 1237 1238
9. T. Hambrock, D.M. Somford, and C. Hoeks Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen J Urol 183 2010 520 527
10. Hambrock T, Somford DM, Hoeks C, et al. Correlation of apparent diffusion coefficient values at 3T MRI with prostate cancer Gleason grade in the peripheral zone. Radiology. In press.
11. M.J. Roobol, F.H. Schroder, and E.D. Crawford A framework for the identification of men at increased risk for prostate cancer J Urol 182 2009 2112 2120